Lilly's next-gen weight loss drug more than doubled Novo Nordisk's in trial
Retatrutide lowered A1C, a blood sugar measure, by 2.2% versus 1.8% for Ozempic, but 7.9% on the 12 mg dose stopped treatment over side effects
Retatrutide lowered A1C, a blood sugar measure, by 2.2% versus 1.8% for Ozempic, but 7.9% on the 12 mg dose stopped treatment over side effects